Time to recurrence ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death Number of deaths over 36 months · stage III and IV cutaneous melanoma
1 finding from 1 review
Adverse events, · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
Overall response rate (ORR), · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).
1 finding from 1 review
Time to recurrence · stage III and IV cutaneous melanoma
1 finding from 1 review
Quality of life ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, · stage III cutaneous melanoma
1 finding from 1 review
Overall response rate (ORR), · stage III cutaneous melanoma
Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in overall response rate (ORR), compared with neoadjuvant immunotherapy (sequential treatment with ipilimumab then… (low certainty).
1 finding from 1 review
Time to response ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · stage III cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in physical signs (overall physical impact) As measured by PMDRS, total score (lower is better) · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
1 finding from 1 review
Level of functioning · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Pain (POSAS 0–10, higher score = more severe pain, VAS 0–10, higher score = more severe pruritus) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pruritus · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review